Close X
Attorney Spotlight

What emerging trend in shareholder litigation does Britt Latham find most interesting in his practice today?    Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

Bass, Berry & Sims Recognized by The M&A Advisor for Transaction of the Year

November 24, 2014

Nashville, Tenn., (November 24, 2014) - Bass, Berry & Sims PLC has been recognized by The M&A Advisor for the firm's work on behalf of AmSurg Corp. (NASDAQ: AMSG) in connection with its July 2014 acquisition of Sheridan Healthcare Inc.

2014 M&A Advisor Award WinnerBass, Berry & Sims received the "M&A Deal of the Year" award in the "Healthcare/Life Sciences Deal of the Year (Over $250MM)" category as part of the 13th Annual M&A Advisor Awards. The Bass, Berry & Sims team was led by Chair of the firm's Healthcare Practice Jim Jenkins and included a team of attorneys from various disciplines that coordinated and completed healthcare regulatory, corporate, real estate, benefits and labor due diligence; negotiated all related deal documents; and handled the related SEC filings required to be made by AmSurg. The firm also represented AmSurg in its common stock, preferred stock and senior notes offerings as well as entering into a new credit facility.

The M&A Advisor reported that more than 130 nominees, representing more than 600 companies, became finalists for this year's awards. An independent judging committee of 11 top M&A experts determined the ultimate recipients of the awards. The awards were announced at the 13th Annual M&A Advisor Awards Gala on November 17 in New York, NY.

About The M&A Advisor
Since 1998, The M&A Advisor has been presenting, recognizing the achievement of and facilitating connections between the world's leading mergers and acquisitions, financing and turnaround professionals with a comprehensive range of services, including M&A SUMMITS, M&A AWARDS, M&A CONNECTS™, M&A LINKS™, MandA.TV and M&A MARKET INTEL™. For more information, please visit www.maadvisor.com.

About Bass, Berry & Sims PLC
With more than 200 attorneys representing numerous publicly traded companies and Fortune 500 businesses, Bass, Berry & Sims has been involved in some of the largest and most significant litigation matters and business transactions in the country. For more information, visit www.bassberry.com.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.